An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Over the last twenty years, the characterization of Alzheimer's disease (AD) patients has progressed from a description of clinical symptomatology followed by neuropathological findings at autopsy to in vivo pathophysiological signatures using cerebrospinal fluid (CSF) and positron emission tomography (PET). Additionally, CSF biomarkers now reflect synaptic pathology, axonal injury and neuroinflammation. Novel techniques are capable of measuring proteins of pathophysiological importance at femtomolar concentrations in blood (e.g. amyloid, tau species and neurofilaments), which enable screening of large populations in the near future. This will be essential for secondary prevention trials and clinical management. However, common diseases such as dementia with Lewy bodies, Parkinson's disease and frontotemporal dementias, are still without reliable diagnostic biomarkers, although emerging techniques show promising pilot results for some of these diseases. This is likely to change in the next few years, which will be crucial to stratify populations enrolling in clinical trials, since pathologies often coexist.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationThe amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationOlsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Self-citationHigh performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report
Nelson, P. T., Dickson, D. W., Trojanowski, J. Q., Jack, C. R., Boyle, P. A., Arfanakis, K., Rademakers, R., Alafuzoff, I., Attems, J., Brayne, C., et al. (2019) · Brain · doi:10.1093/brain/awz099 · Cited by 1,547
Neurofilament light chain as a biomarker in neurological disorders
Gaetani, L., Blennow, K., Calabresi, P., Di Filippo, M., Parnetti, L., & Zetterberg, H. (2019) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-320106 · Cited by 1,334
Self-citationBeach, T. G., Monsell, S. E., Phillips, L. E., & Kukull, W. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31824b211b · Cited by 1,103 · cited 1×
“often coexist, which is seen at a rate of 27-68% among the groups examined, according to several recent studies [1-3].”
ResultHigh-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Schindler, S. E., Bollinger, J. G., Ovod, V., Mawuenyega, K. G., Li, Y., Gordon, B. A., Holtzman, D. M., Morris, J. C., Benzinger, T. L. S., Xiong, C., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008081 · Cited by 885
Hansson, O., Seibyl, J., Stomrud, E., Zetterberg, H., Trojanowski, J. Q., Bittner, T., Lifke, V., Corradini, V., Eichenlaub, U., Batrla, R., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.010 · Cited by 808
Self-citationTREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis
Kleinberger, G., Yamanishi, Y., Suárez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., Struyfs, H., Pettkus, N., Wenninger-Weinzierl, A., Mazaheri, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009093 · Cited by 798
Self-citationRobinson, J. L., Lee, E. B., Xie, S. X., Rennert, L., Suh, E., Bredenberg, C., Caswell, C., Van Deerlin, V. M., Yan, N., Yousef, A., et al. (2018) · Brain · doi:10.1093/brain/awy146 · Cited by 729
Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease
Masliah, E., Mallory, M., Alford, M., DeTeresa, R., Hansen, L. A., McKeel, D. W., & Morris, J. C. (2001) · Neurology · doi:10.1212/wnl.56.1.127 · Cited by 720
CSF and blood biomarkers for Parkinson's disease
Parnetti, L., Gaetani, L., Eusebi, P., Paciotti, S., Hansson, O., El-Agnaf, O., Mollenhauer, B., Blennow, K., & Calabresi, P. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30024-9 · Cited by 673
Self-citationPlasma β-amyloid in Alzheimer's disease and vascular disease
Janelidze, S., Stomrud, E., Palmqvist, S., Zetterberg, H., van Westen, D., Jeromin, A., Song, L., Hanlon, D., Tan Hehir, C. A., Baker, D., et al. (2016) · Scientific Reports · doi:10.1038/srep26801 · Cited by 626
Self-citationMielke, M. M., Hagen, C. E., Xu, J., Chai, X., Vemuri, P., Lowe, V. J., Airey, D. C., Knopman, D. S., Roberts, R. O., Machulda, M. M., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.013 · Cited by 621
Tau Kinetics in Neurons and the Human Central Nervous System
Sato, C., Barthélemy, N. R., Mawuenyega, K. G., Patterson, B. W., Gordon, B. A., Jockel-Balsarotti, J., Sullivan, M., Crisp, M. J., Kasten, T., Kirmess, K. M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.02.015 · Cited by 586
Hansson, O., Lehmann, S., Otto, M., Zetterberg, H., & Lewczuk, P. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0485-0 · Cited by 585
Self-citationSuárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506123 · Cited by 522
Self-citationYKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease
Craig-Schapiro, R., Perrin, R. J., Roe, C. M., Xiong, C., Carter, D., Cairns, N. J., Mintun, M. A., Peskind, E. R., Li, G., Galasko, D. R., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.025 · Cited by 504
Plasma tau in Alzheimer disease
Mattsson, N., Zetterberg, H., Janelidze, S., Insel, P. S., Andreasson, U., Stomrud, E., Palmqvist, S., Baker, D., Tan Hehir, C. A., Jeromin, A., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003246 · Cited by 502
Self-citationPalmqvist, S., Janelidze, S., Stomrud, E., Zetterberg, H., Karl, J., Zink, K., Bittner, T., Mattsson, N., Eichenlaub, U., Blennow, K., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1632 · Cited by 435
Self-citationChen, M.-K., Mecca, A. P., Naganawa, M., Finnema, S. J., Toyonaga, T., Lin, S.-F., Najafzadeh, S., Ropchan, J., Lu, Y., McDonald, J. W., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1836 · Cited by 431
TDP-43 stage, mixed pathologies, and clinical Alzheimer’s-type dementia
James, B. D., Wilson, R. S., Boyle, P. A., Trojanowski, J. Q., Bennett, D. A., & Schneider, J. A. (2016) · Brain · doi:10.1093/brain/aww224 · Cited by 407
CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease
Janelidze, S., Mattsson, N., Stomrud, E., Lindberg, O., Palmqvist, S., Zetterberg, H., Blennow, K., & Hansson, O. (2018) · Neurology · doi:10.1212/wnl.0000000000006082 · Cited by 359
Self-citationPalmqvist, S., Insel, P. S., Stomrud, E., Janelidze, S., Zetterberg, H., Brix, B., Eichenlaub, U., Dage, J. L., Chai, X., Blennow, K., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201911170 · Cited by 353
Self-citationInitiative, F. T. A. D. N., Suárez-Calvet, M., Morenas-Rodríguez, E., Kleinberger, G., Schlepckow, K., Araque Caballero, M. Á., Franzmeier, N., Capell, A., Fellerer, K., Nuscher, B., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0301-5 · Cited by 347
Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status
Piccio, L., Deming, Y., Del-Águila, J. L., Ghezzi, L., Holtzman, D. M., Fagan, A. M., Fenoglio, C., Galimberti, D., Borroni, B., & Cruchaga, C. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1533-5 · Cited by 337
NPTX2 and cognitive dysfunction in Alzheimer’s Disease
Xiao, M.-F., Xu, D., Craig, M. T., Pelkey, K. A., Chien, C.-C., Shi, Y., Zhang, J., Resnick, S., Pletnikova, O., Salmon, D., et al. (2017) · eLife · doi:10.7554/elife.23798 · Cited by 316
Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes
Verberk, I. M. W., Slot, R. E., Verfaillie, S. C. J., Heijst, H., Prins, N. D., van Berckel, B. N. M., Scheltens, P., Teunissen, C. E., & van der Flier, W. M. (2018) · Annals of Neurology · doi:10.1002/ana.25334 · Cited by 315
Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease
McDade, E., Wang, G., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Holtzman, D. M., Cairns, N. J., Goate, A. M., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006277 · Cited by 314
Glial activation and inflammation along the Alzheimer’s disease continuum
Nordengen, K., Kirsebom, B.-E., Henjum, K., Selnes, P., Gísladóttir, B., Wettergreen, M., Torsetnes, S. B., Grøntvedt, G. R., Waterloo, K. K., Aarsland, D., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1399-2 · Cited by 274
Suárez-Calvet, M., Araque Caballero, M. Á., Kleinberger, G., Bateman, R. J., Fagan, A. M., Morris, J. C., Levin, J., Danek, A., Ewers, M., Haass, C., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1767 · Cited by 272
Staging β -Amyloid Pathology With Amyloid Positron Emission Tomography
Mattsson, N., Palmqvist, S., Stomrud, E., Vogel, J., & Hansson, O. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2214 · Cited by 237
Randall, J., Mörtberg, E., Provuncher, G. K., Fournier, D. R., Duffy, D. C., Rubertsson, S., Blennow, K., Zetterberg, H., & Wilson, D. H. (2013) · Resuscitation · doi:10.1016/j.resuscitation.2012.07.027 · Cited by 230
Self-citationSubtyping of circulating exosome-bound amyloid β reflects brain plaque deposition
Lim, C. Z. J., Zhang, Y., Chen, Y., Zhao, H., Stephenson, M. C., Ho, N. R. Y., Chen, Y., Chung, J., Reilhac, A., Loh, T. P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09030-2 · Cited by 209
Skillbäck, T., Rosén, C., Asztely, F., Mattsson, N., Blennow, K., & Zetterberg, H. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.6455 · Cited by 207
Self-citationThe pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease
Öhrfelt, A., Brinkmalm, A., Dumurgier, J., Brinkmalm, G., Hansson, O., Zetterberg, H., Bouaziz-Amar, E., Hugon, J., Paquet, C., & Blennow, K. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0208-8 · Cited by 184
Self-citationCerebrospinal fluid neurogranin and YKL ‐40 as biomarkers of Alzheimer's disease
Janelidze, S., Hertze, J., Zetterberg, H., Landqvist Waldö, M., Santillo, A., Blennow, K., & Hansson, O. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.266 · Cited by 179
Self-citationCicognola, C., Brinkmalm, G., Wahlgren, J., Portelius, E., Gobom, J., Cullen, N. C., Hansson, O., Parnetti, L., Constantinescu, R., Wildsmith, K., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1948-2 · Cited by 168
Self-citationSutphen, C. L., McCue, L., Herries, E. M., Xiong, C., Ladenson, J. H., Holtzman, D. M., Fagan, A. M., & On behalf of, A. D. N. I. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.012 · Cited by 162
Tau Kinetics in Neurons and the Human Central Nervous System
Sato, C., Barthélemy, N. R., Mawuenyega, K. G., Patterson, B. W., Gordon, B. A., Jockel-Balsarotti, J., Sullivan, M., Crisp, M. J., Kasten, T., Kirmess, K. M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.04.035 · Cited by 154
Dage, J. L., Wennberg, A. M. V., Airey, D. C., Hagen, C. E., Knopman, D. S., Machulda, M. M., Roberts, R. O., Jack, C. R., Petersen, R. C., & Mielke, M. M. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.06.001 · Cited by 145
Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease
Schindler, S. E., Li, Y., Todd, K. W., Herries, E. M., Henson, R. L., Gray, J. D., Wang, G., Graham, D. L., Shaw, L. M., Trojanowski, J. Q., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.12.019 · Cited by 101
Staffaroni, A. M., Kramer, A. O., Casey, M., Kang, H., Rojas, J. C., Orrú, C. D., Caughey, B., Allen, I. E., Kramer, J. H., Rosen, H. J., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1071 · Cited by 100
Self-citationPlasma tau is increased in frontotemporal dementia
Foiani, M. S., Woollacott, I. O., Heller, C., Bocchetta, M., Heslegrave, A., Dick, K. M., Russell, L. L., Marshall, C. R., Mead, S., Schott, J. M., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-317260 · Cited by 64
Self-citation
Cited by
Tauopathies: new perspectives and challenges
Zhang, Y., Wu, K.-M., Yang, L., Dong, Q., & Yu, J.-T. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00533-z · Cited by 323
Janelidze, S., Palmqvist, S., Leuzy, A., Stomrud, E., Verberk, I. M. W., Zetterberg, H., Ashton, N. J., Pesini, P., Sarasa, L., Allué, J. A., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12395 · Cited by 188
Self-citationIncidence of Syndromes Associated With Frontotemporal Lobar Degeneration in 9 European Countries
Logroscino, G., Piccininni, M., Graff, C., Hardiman, O., Ludolph, A. C., Moreno, F., Otto, M., Remes, A. M., Rowe, J. B., Seelaar, H., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2022.5128 · Cited by 91
Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer’s Disease
Rani, S., Dhar, S. B., Khajuria, A., Gupta, D., Jaiswal, P. K., Singla, N., Kaur, M., Singh, G., & Barnwal, R. P. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01330-y · Cited by 48
CSF Biomarkers of Alzheimer Disease in Patients With Concomitant α-Synuclein Pathology
Cousins, K. A. Q., Arezoumandan, S., Shellikeri, S., Ohm, D., Shaw, L. M., Grossman, M., Wolk, D., McMillan, C. T., Chen-Plotkin, A., Lee, E., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000201202 · Cited by 25
Self-citation
Metadata
- Authors
- Simrén, J., Ashton, N. J., Blennow, K., & Zetterberg, H.
- Venue
- Current Opinion in Neurobiology
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 61
- Pages
- 29-39
- ISSN
- 0959-4388 (ISSN-L)
- OpenAlex
- W2995968697
- Cited by
- 107
- References
- 46
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.